… with DM undergoing high-risk PCI (14) and those with previous myocardial infarction (15)
or stable coronary artery disease (16). A comparison of absolute reductions by prasugrel over …

… Ticagrelor plus aspirin compared to aspirin alone in patients with stable coronary artery
disease (CAD), diabetes, and a history of percutaneous coronary intervention (PCI). The findings …

… drugs in patients with SCAD (… ticagrelor is used in patients with SCAD who receive PCI,
and its use is increasing, especially in high-risk diabetic patients or in complex coronary artery …

… coronary artery disease (CAD). Therefore, understanding the risk profile as well as the …
randomized patients with stable CAD and diabetes but no prior MI to DAPT with ticagrelor plus …

… been conducted on ticagrelor added to aspirin for managing patients with SCD and diabetes.
… ticagrelor plus aspirin for patients with SCD and diabetes by using the THEMIS trial data. …

… risk patients with stable coronary artery disease and diabetes without previous myocardial
infarction or stroke, ticagrelor… Identification of patients who could derive the greatest net benefit …

… Factors that might favour CABG over PCI as a revascularisation strategy include triple-vessel
or left main coronary artery disease, particularly in patients with diabetes mellitus and those …

… DM patients with stable coronary artery disease and no prior stroke or myocardial infarction,
showed that although ticagrelor in … However, patients with history of percutaneous coronary …

… These two risk factors of coronary heart disease have also been shown to synergistically
amplify the hazards when they co-exist. Reports published nearly two decades ago showed …

… In conclusion, in the REACH registry, over a quarter of patients with diabetes and stable
coronary artery disease were ‘THEMIS eligible’ - a sizeable population. Given their higher event …